uniQure N.V. $QURE Shares Sold by Privium Fund Management B.V.

Key Points

• Privium Fund Management B.V. sold 131,653 shares of uniQure N.V., reducing its stake by 22.7%, and now owns 447,486 shares valued at approximately $6.26 million.
• Analysts have set multiple new price targets for uniQure, with estimates rising as high as $80.00 from Cantor Fitzgerald, reflecting growing optimism about the company's prospects.
• CEO Matthew C. Kapusta and CFO Christian Klemt recently sold a combined total of $10.3 million in company shares, indicating a significant reduction in their ownership positions.

Privium Fund Management B.V. decreased its holdings in uniQure N.V. (NASDAQ:QURE - Free Report) by 22.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 447,486 shares of the biotechnology company's stock after selling 131,653 shares during the quarter. uniQure comprises 1.4% of Privium Fund Management B.V.'s investment portfolio, making the stock its 13th largest holding. Privium Fund Management B.V. owned 0.82% of uniQure worth $6,260,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vestal Point Capital LP raised its holdings in shares of uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after buying an additional 1,767,572 shares during the last quarter. Aberdeen Group plc increased its position in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after acquiring an additional 706,216 shares during the period. Affinity Asset Advisors LLC purchased a new stake in uniQure during the 1st quarter valued at approximately $4,240,000. Russell Investments Group Ltd. purchased a new stake in uniQure during the 1st quarter valued at approximately $3,218,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in uniQure during the 1st quarter worth approximately $2,562,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

QURE has been the subject of several analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of uniQure in a research note on Wednesday, October 8th. Chardan Capital boosted their price objective on shares of uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a research note on Thursday, September 25th. Cantor Fitzgerald raised their target price on shares of uniQure from $47.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, September 25th. Stifel Nicolaus lifted their target price on shares of uniQure from $30.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. Finally, Leerink Partners increased their price target on shares of uniQure from $48.00 to $68.00 and gave the stock an "outperform" rating in a report on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, uniQure presently has an average rating of "Moderate Buy" and an average price target of $71.75.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the company's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares in the company, valued at $27,009,282.84. This represents a 25.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares of the company's stock, valued at approximately $11,975,150. This represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 244,316 shares of company stock worth $10,328,181 in the last three months. Corporate insiders own 4.79% of the company's stock.

uniQure Stock Performance

NASDAQ:QURE opened at $63.92 on Tuesday. The firm's fifty day simple moving average is $31.77 and its 200-day simple moving average is $20.10. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock has a market cap of $3.51 billion, a PE ratio of -16.31 and a beta of 0.56. uniQure N.V. has a fifty-two week low of $5.35 and a fifty-two week high of $65.14.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $5.26 million during the quarter, compared to analysts' expectations of $5.00 million. Analysts expect that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.